Tracing the origins of metastasis

Journal of Pathology

Volumn 223, Issue 2, 2011, Pages 196-205

  Nguyen, Don X ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer stem cells; epigenetics; genetics; metastasis; microenvironment; prognosis; tumour heterogeneity

Indexed keywords

MICRORNA; UNTRANSLATED RNA;

CANCER CELL; CANCER STEM CELL; CARCINOGENESIS; CELL LINEAGE; DNA POLYMORPHISM; EPIGENETICS; GENE AMPLIFICATION; GENE DOSAGE; GENE FUSION; GENE MUTATION; GENETIC TRAIT; GENETIC VARIABILITY; HUMAN; METASTASIS; MICROENVIRONMENT; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW;

EID: 78650001948     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2801     Document Type: Review

References (130)

1. Weiss L,. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metast Rev 2000; 19: I-XI, 193-383.
2. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
3. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2: 563-572.
4. Pantel K, Brakenhoff RH,. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456.
5. Christofori G,. New signals from the invasive front. Nature 2006; 441: 444-450.
6. Gupta GP, Massague J,. Cancer metastasis: building a framework. Cell 2006; 127: 679-695.
7. Steeg PS,. Tumour metastasis: mechanistic insights and clinical challenges. Nat Med 2006; 12: 895-904.
8. Chiang AC, Massague J,. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
9. Talmadge JE, Fidler IJ,. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 2010; 70: 5649-5669.
10. Fidler IJ,. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458.
11. McGowan PM, Kirstein JM, Chambers AF,. Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. Future Oncol 2009; 5: 1083-1098.
12. Hess KR, Varadhachary GR, Taylor SH, et al., Metastatic patterns in adenocarcinoma. Cancer 2006; 106: 1624-1633.
13. Ewing J,. Neoplastic Diseases, 6th edn. W. B. Saunders: Philadelphia, PA, 1928.
14. Bos PD, Zhang XH, Nadal C, et al., Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
15. Kang Y, Siegel PM, Shu W, et al., A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3: 537-549.
16. Minn AJ, Gupta GP, Siegel PM, et al., Genes that mediate breast cancer metastasis to lung. Nature 2005; 436: 518-524.
17. Disibio G, French SW,. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med 2008; 132: 931-939.
18. van de Wouw AJ, Jansen RL, Speel EJ, et al., The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003; 14: 191-196.
19. O'Reilly MS, Holmgren L, Shing Y, et al., Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315-328.
20. Ebos JM, Lee CR, Cruz-Munoz W, et al., Accelerated metastasis after short-term treatment with a potent inhibitor of tumour angiogenesis. Cancer Cell 2009; 15: 232-239.
21. Paez-Ribes M, Allen E, Hudock J, et al., Antiangiogenic therapy elicits malignant progression of tumours to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
22. Pantel K, Brakenhoff RH, Brandt B,. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-340.
23. Braun S, Vogl FD, Naume B, et al., A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802. (Pubitemid 41215488)
24. Reya T, Morrison SJ, Clarke MF, et al., Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
25. Palmieri D, Chambers AF, Felding-Habermann B, et al., The biology of metastasis to a sanctuary site. Clin Cancer Res 2007; 13: 1656-1662.
26. Jain RK, Duda DG, Willett CG, et al., Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009; 6: 327-338.
27. Loberg RD, Bradley DA, Tomlins SA, et al., The lethal phenotype of cancer: the molecular basis of death due to malignancy. CA Cancer J Clin 2007; 57: 225-241.
28. Joyce JA, Pollard JW,. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
29. Psaila B, Lyden D,. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009; 9: 285-293.
30. Bondar T, Medzhitov R,. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 2010; 6: 309-322.
31. Wu M, Pastor-Pareja JC, Xu T,. Interaction between Ras (V12) and scribbled clones induces tumour growth and invasion. Nature 2010; 463: 545-548.
32. McAllister SS, Gifford AM, Greiner AL, et al., Systemic endocrine instigation of indolent tumour growth requires osteopontin. Cell 2008; 133: 994-1005.
33. Kim MY, Oskarsson T, Acharyya S, et al., Tumour self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
34. Nguyen DX, Massague J,. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341-352.
35. Fearon ER, Vogelstein B,. A genetic model for colorectal tumourigenesis. Cell 1990; 61: 759-767.
36. Talmadge JE, Wolman SR, Fidler IJ,. Evidence for the clonal origin of spontaneous metastases. Science 1982; 217: 361-363.
37. Marusyk A, Polyak K,. Tumour heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805: 105-117.
38. Strien L, Leidenius M, von Smitten K, et al., Concordance between HER-2 and steroid hormone receptor expression between primary breast cancer, sentinel node metastases, and isolated tumour cells. Pathol Res Pract 2010; 206: 253-258.
39. Mehra R, Tomlins SA, Yu J, et al., Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008; 68: 3584-3590.
40. Ramaswamy S, Ross KN, Lander ES, et al., A molecular signature of metastasis in primary solid tumours. Nat Genet 2003; 33: 49-54.
41. Fan C, Oh DS, Wessels L, et al., Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
42. Yu J, Rhodes DR, Tomlins SA, et al., A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res 2007; 67: 10657-10663.
43. Ma L, Teruya-Feldstein J, Weinberg RA,. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
44. Tavazoie SF, Alarcon C, Oskarsson T, et al., Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
45. Gibbons DL, Lin W, Creighton CJ, et al., Contextual extracellular cues promote tumour cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 2009; 23: 2140-2151.
46. Valastyan S, Reinhardt F, Benaich N, et al., A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-1046.
47. Gupta RA, Shah N, Wang KC, et al., Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464: 1071-1076.
48. Jones S, Chen WD, Parmigiani G, et al., Comparative lesion sequencing provides insights into tumour evolution. Proc Natl Acad Sci USA 2008; 105: 4283-4288.
49. Liu W, Laitinen S, Khan S, et al., Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009; 15: 559-565.
50. Girard N, Ostrovnaya I, Lau C, et al., Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers. Clin Cancer Res 2009; 15: 5184-5190.
51. Kerbel RS, Waghorne C, Korczak B, et al., Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv 1988; 7: 597-629.
52. Bernards R, Weinberg RA,. A progression puzzle. Nature 2002; 418: 823.
53. Adler AS, Lin M, Horlings H, et al., Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet 2006; 38: 421-430.
54. Wong DJ, Liu H, Ridky TW, et al., Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008; 2: 333-344.
55. Ma L, Young J, Prabhala H, et al., miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
56. Lang GA, Iwakuma T, Suh YA, et al., Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 2004; 119: 861-872.
57. Olive KP, Tuveson DA, Ruhe ZC, et al., Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860.
58. Muller PA, Caswell PT, Doyle B, et al., Mutant p53 drives invasion by promoting integrin recycling. Cell 2009; 139: 1327-1341.
59. Adorno M, Cordenonsi M, Montagner M, et al., A mutant p53/Smad complex opposes p63 to empower TGFβ-induced metastasis. Cell 2009; 137: 87-98.
60. Cifone MA, Fidler IJ,. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 1981; 78: 6949-6952.
61. Steeg PS,. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003; 3: 55-63.
62. Klein CA, Stoecklein NH,. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009; 69: 5285-5288.
63. Wu JM, Fackler MJ, Halushka MK, et al., Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumours and their multifocal metastases. Clin Cancer Res 2008; 14: 1938-1946.
64. Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al., Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986.
65. Yegnasubramanian S, Haffner MC, Zhang Y, et al., DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumour heterogeneity. Cancer Res 2008; 68: 8954-8967.
66. Park S, Holmes-Tisch AJ, Cho EY, et al., Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumours and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009; 4: 809-815.
67. Sun M, Behrens C, Feng L, et al., HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumours. Clin Cancer Res 2009; 15: 4829-4837.
68. Stoecklein NH, Klein CA,. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer; 126: 589-598.
69. Schmidt-Kittler O, Ragg T, Daskalakis A, et al., From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003; 100: 7737-7742.
70. Klein CA,. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009; 9: 302-312.
71. Crawford NP, Ziogas A, Peel DJ, et al., Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006; 8: R16.
72. Bell DW,. Our changing view of the genomic landscape of cancer. J Pathol 2010; 220: 231-243.
73. Metzker ML,. Sequencing technologies-the next generation. Nat Rev Genet 2010; 11: 31-46.
74. Shah SP, Morin RD, Khattra J, et al., Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461: 809-813.
75. Ding L, Ellis MJ, Li S, et al., Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
76. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730.
77. Brabletz T, Jung A, Spaderna S, et al., Opinion: migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005; 5: 744-749.
78. Navin N, Krasnitz A, Rodgers L, et al., Inferring tumour progression from genomic heterogeneity. Genome Res 2010; 20: 68-80.
79. Nagrath S, Sequist LV, Maheswaran S, et al., Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-1239.
80. Schwarzenbach H, Pantel K, Kemper B, et al., Comparative evaluation of cell-free tumour DNA in blood and disseminated tumour cells in bone marrow of patients with primary breast cancer. Breast Cancer Res 2009; 11: R71.
81. Schwarzenbach H, Alix-Panabieres C, Muller I, et al., Cell-free tumour DNA in blood plasma as a marker for circulating tumour cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-1038.
82. Schwarzenbach H, Stoehlmacher J, Pantel K, et al., Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci 2008; 1137: 190-196.
83. Fidler IJ,. Selection of successive tumour lines for metastasis. Nat New Biol 1973; 242: 148-149.
84. Fidler IJ, Kripke ML,. Metastasis results from pre-existing variant cells within a malignant tumour. Science 1977; 197: 893-895.
85. Nicolson GL, Winkelhake JL,. Organ specificity of blood-borne tumour metastasis determined by cell adhesion? Nature 1975; 255: 230-232.
86. Talmadge JE, Fidler IJ,. Cancer metastasis is selective or random depending on the parent tumour population. Nature 1982; 297: 593-594.
87. Weiss L,. Dynamic aspects of cancer cell populations in metastasis. Am J Pathol 1979; 97: 601-608.
88. Weiss L,. Random and non-random processes in metastasis, and metastatic inefficiency. Invas Metast 1983; 3: 193-207.
89. Weiss L,. Metastatic inefficiency. Adv Cancer Res 1990; 54: 159-211.
90. Luzzi KJ, MacDonald IC, Schmidt EE, et al., Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-873.
91. Shackleton M, Quintana E, Fearon ER, et al., Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009; 138: 822-829.
92. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al., Prospective identification of tumourigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988. (Pubitemid 36418143)
93. Charafe-Jauffret E, Ginestier C, Iovino F, et al., Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009; 69: 1302-1313.
94. Pece S, Tosoni D, Confalonieri S, et al., Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
95. Fillmore CM, Kuperwasser C,. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008; 10: R25.
96. Shipitsin M, Campbell LL, Argani P, et al., Molecular definition of breast tumour heterogeneity. Cancer Cell 2007; 11: 259-273.
97. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
98. Morel AP, Lievre M, Thomas C, et al., Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008; 3: e2888.
99. Thiery JP, Acloque H, Huang RY, et al., Epithelial-mesenchymal transitions in development and disease. Cell 2009; 139: 871-890.
100. Balic M, Lin H, Young L, et al., Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006; 12: 5615-5621.
101. Theodoropoulos PA, Polioudaki H, Agelaki S, et al., Circulating tumour cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288: 99-106.
102. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
103. Singh SK, Hawkins C, Clarke ID, et al., Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
104. O'Brien CA, Pollett A, Gallinger S, et al., A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
105. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al., Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115.
106. + cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009; 106: 16281-16286.
107. - metastatic colon cancer cells initiate tumours. J Clin Invest 2008; 118: 2111-2120.
108. Hermann PC, Huber SL, Herrler T, et al., Distinct populations of cancer stem cells determine tumour growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
109. Muller A, Homey B, Soto H, et al., Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-56.
110. + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010; 6: 603-615.
111. Quintana E, Shackleton M, Sabel MS, et al., Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
112. Boiko AD, Razorenova OV, van de Rijn M, et al., Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
113. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al., A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumour growth. Cell 2010; 141: 583-594.
114. Smid M, Wang Y, Zhang Y, et al., Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68: 3108-3114.
115. Podsypanina K, Du YC, Jechlinger M, et al., Seeding and propagation of untransformed mouse mammary cells in the lung. Science 2008; 321: 1841-1844.
116. Curtis SJ, Sinkevicius KW, Li D, et al., Primary tumour genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell; 7: 127-133.
117. Shackleton M, Vaillant F, Simpson KJ, et al., Generation of a functional mammary gland from a single stem cell. Nature 2006; 439: 84-88.
118. Teissedre B, Pinderhughes A, Incassati A, et al., MMTV-Wnt1 and -IΔN89β-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumours. PLoS One 2009; 4: e4537.
119. Paget S,. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metast Rev 1989; 8: 98-101.
120. Steeg PS, Theodorescu D,. Metastasis: a therapeutic target for cancer. Nat Clin Pract Oncol 2008; 5: 206-219.
121. Aragon-Ching JB, Zujewski JA,. CNS metastasis: an old problem in a new guise. Clin Cancer Res 2007; 13: 1644-1647.
122. Omuro AM, Kris MG, Miller VA, et al., High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung carcinoma after response to gefitinib. Cancer 2005; 103: 2344-2348.
123. Liu R, Wang X, Chen GY, et al., The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007; 356: 217-226.
124. Ben-Porath I, Thomson MW, Carey VJ, et al., An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumours. Nat Genet 2008; 40: 499-507.
125. Varambally S, Yu J, Laxman B, et al., Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
126. Bild AH, Yao G, Chang JT, et al., Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
127. Lamb J, Crawford ED, Peck D, et al., The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006; 313: 1929-1935.
128. Zhang XH, Wang Q, Gerald W, et al., Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009; 16: 67-78.
129. Carretero J, Shimamura T, Rikova K, et al., Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumours. Cancer Cell 2010; 17: 547-559.
130. Du J, Bernasconi P, Clauser KR, et al., Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 2009; 27: 77-83.